Гонадотоксичность терапии лимфомы Ходжкина у подростков и молодых мужчин: актуальность проблемы и пути решения (обзор литературы)
Аннотация
В настоящее время лимфома Ходжкина (ЛХ) – одно из наиболее курабельных опухолевых заболеваний, при этом более половины заболевших являются лицами мужского пола в возрасте до 35 лет. Гонадотоксичность служит одним из наиболее частых отдаленных последствий терапии ЛХ, что ассоциировано со значительным ухудшением качества жизни больных. В настоящей статье обобщены данные о частоте встречаемости и факторах риска развития гонадотоксичности у лиц мужского пола с ЛХ. Показано, что проведение химиотерапии с включением алкилирующих препаратов и лучевая терапия могут приводить к развитию гонадотоксичности у значительного числа больных. Рассмотрены современные возможности проведения криоконсервации спермы до начала противоопухолевой терапии.
Об авторах
А. А. Винокуров
ФГУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии
Минздравсоцразвития России
Россия
Россия
С. Р. Варфоломеева
ФГУ Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии
Минздравсоцразвития России
Россия
Россия
Д. И. Тарусин
Научно-практический центр детской и подростковой андрологии Департамента здравоохранения города Москвы
Россия
Россия
Список литературы
1. Семочкин С.В., Лория С.С., Румянцев А.Г. и соавт. Лечение лимфомы Ходжкина у подростков и молодых взрослых. Онкогематология 2008;1–2:18–26.
2. De Vita V.T., Hellman S., Rosenberg S.A., eds. Cancer: Principles and Practice of Oncology. Volume 2–6. Chapter 45. Philadelphia: Lippincott-Raven Publishers, 2001, p. 917.
3. Ries L.A.G., Miller B.A., Hankey B.F., National Cancer Institute. NIH Publication Number 94, 1994, p. 2789.
4. Bleyer W.A., O’Learly M., Barr R. & Ries L.A., eds. (2006). Cancer Epidemiology in Older Adolescents and Young Adults 15–29 Years of Age, Including SEER Incidence and Survival, 1975–2000. Oncologist;11:590–601.
5. Двойрин В.В., Аксель Е.М., Трапезников Н.Н. Статистика злокачественных новообразований в России и некоторых других странах СНГ в 1994 г. (в 2 ч.). М., 1995.
6. Armitage J.O. Early-stage Hodgkin’s lymphoma. N Engl J Med 2010 Aug 12;363(7):653–62.
7. Hewitt M., Weiner S.L., Simone J.V. Childhood Cancer survivorship: improving care and quality of life: institute of Medicine. Washington DC: The National Academy Press;2003:20–36.
8. Bailliere’s Clinical Haematology. Int Pract and Res. Hodgkin’s Disease/ V. Diehl. London-Philadelphia-Sydney: Bailliere Tindal, 1996, p. 232.
9. Donaldson S.S., Link M.P. Combined modality reatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin disease. J Clin Oncology 1987;5:742–9.
10. Armitage J.O. Long-term toxicity of the treatment of Hodgkin’s disease. Ann Oncol 1998;9(Suppl 5):133–6.
11. Swerdlov A.J., Barber J.A., Hudson G.V. et al. J Clin Oncol 2000;18(3):498–508.
12. Meistrich M.L., Vassilopoulou-Sellin R., Lipshultz L.I. Adverse effects of treatment: gonadal dysfunction. In: De Vita V.T., Hellman S., Rosenberg S.A., eds. Cancer: principles and practice of oncology. ed. 7. Philadelphia: Lippincott Williams & Wilkins, 2005, p. 2560–74.
13. Schrader M., Muller M., Straub B., Miller K. The impact of chemotherapy on male fertility: a survey of the biologic basis and clinical aspects. Reprod Toxicol 2001;15:611–7.
14. Myrehaug S., Pintilie M. et al. A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood 2010Sep30;116(13):2237–40. Epub 2010Jul 1
15. Нишлаг Э., Бере Г. и др. Андрология .М.: МИА, 2005. Стр. 35–39.
16. Нишлаг Э., Бере Г. и др. Андрология. М.: МИА, 2005. Стр. 48–49.
17. Muller H.L., Klinkhammer-Schalkie M. et al. Gonadal function of young adults after therapy of malignancies during childhood or adolescence. Eur J Pediatr 1996;155(9):763–9.
18. Thomson A.B., Critchley H.O., Kelnar C.J., Wallace W.H. (2002). Late reproductive sequelae following treatment of childhood cancer and options for fertility preservation. Best Pract Res Clin Endocrinol Metab 16:311–34.
19. Brougham M.F., Kelnar C.J., Sharpe R.M., Wallace W.H. Male fertility following childhood cancer: current concepts and future therapies. Asian J Androl 2003 Dec;5(4):325–37.
20. Sieniawski M., Reineke T., Nogova L., Josting A., Pfistner A., Diehl V., Engert A. Fertility in male patients with advanced HL treated with BEACOPP. Blood 2008 Jan 1;111(1):71–6.
21. Schwartz C.L., Hobbie W.L. et al. Survivors of Childhood And Adolescent Cancer, ed 2. Chapter 3, p. 17–34.
22. Vogel E.W., Nivard M.J. International Commission for Protection Against Environmental Mutagens and Carcinogens. The subtlety of alkylating agents in reactions with biological macromolecules. Mutat Res 1994 Feb1;305(1):13–32.
23. Vogel E.W., Barbin A., Nivard M.J., Bartsch H. Nucleophilic selectivity of alkylating agents and their hypermutability in Drosophila as predictors of carcinogenic potency in rodents. Carcinogenesis 1990 Dec;11(12):2211–7.
24. Ehrenberg L. Covalent binding of genotoxic agents to proteins and nucleic acids. IARC Sci Pub 1984;(59):107–14.
25. Angerer J., Ewers U., Wilhelm M. Human biomonitoring: state of the art. Int J Hyg Environ Health 2007 May;210(3–4):201–28.
26. Puscheck E., Philip P.A., Jeyendran R.S. Male fertility preservation and cancer treatment. Cancer Treat Rev 2004 Apr;30(2):173–80.
27. Hamilton V.M., Norris C., Bunin N., Goldwein J.W., Bunin G.R., Lange B., Meadows A.T. Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease. J Pediatr Hematol Oncol 2001;23(2):84–8.
28. Thomson A.B., Critchley H.O., Kelnar C.J., Wallace W.H. Late reproductive sequelae following treatment of childhood cancer and options for fertility preservation. Best Pract Res Clin Endocrinol Metab 2002;16:311–34.
29. Marmor D., Duyck F. Male reproductive potential after MOPP therapy for Hodgkin’s Disease. Andrologia 1995;27:99–106.
30. Viviani S., Ragini G., Santoro A. et al. Testicular disfunction in Hodgkin’s disease before and after treatment. Eur J Cancer 1991;27:1389–92.
31. Bonadonna G., Santoro A., Vivani S., Lombardi G., Ragini G. Gonadal Damage in Hodgkin’s disease for cancer chemotherapeutic regimens. Arch Toxicol 1984;1:140–5.
32. Tal R., Botchan A., Hauser R., Yogev L., Paz G., Yavevetz H. Follow-up sperm concentration and motility in patients with lymphoma. Hum Reprod 2000 Sep;15(9):1985–8.
33. Donaldson S.S., Hudson M.M., Lamborn K.R., Link M.P., Kun L., Billett A.L., Marcus K.C., Hurwitz C.A.,
34. Young J.A., Tarbell N.J., Weinstein H.J. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, earlystage Hodgkin’s disease: results of a prospective clinical trial. J Clin Oncol 2002;20:3081–7.
35. Hansen P.V., Trykker H. et al. Long-term recovery of spermatogenesis after radiotherapy in patients with testicular cancer. Radiother Oncol 1990;18:117–25.
36. Lee S.J., Schover L.R., Partridge A.H. et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917–31.
37. Kinsella T.J., Trivette G. et al. Long-term follow-up of testicular function following radiation therapy for early-stage Hodgkin’s disease. J Clin Oncol 1989;7:718–24.
38. Howell S.J., Shalett S.M. Spermatogenesis After Cancer Treatment: Damage and Recovery. J Natl Cancer Inst Monogr 2005;34:12–7.
39. Hahn E.W., Feingold S.M., Nisce L. Aspermia and recovery of spermatogenesis in cancer patients following incidental gonadal irradiation during treatment: a progress report. Radiology 1976;119:223–5.
40. Kinsella T.J., Trivette G., Rowland J., Sorace R., Miller R., Fraass B. et al. Longterm follow-up of testicular function following adiation therapy for early-stage Hodgkin’s disease. J Clin Oncol 1989;7:718–24.
41. Anserini P.C.S., Spinelli S., Costa M., Conte N., Copello F., Bacigalupo A.Т. Semen analysis following allogeneic bone marrow ransplantation. Additional data for evidencebased counselling. Bone Marrow Transplant 2002;30:447–51.
42. Socie G., Salooja N. et al. Nonmalignant late effects aftеr allogenetic stem cell transplantation. Blood 2003;101:3373–85.
43. Res U., Res P., Kastelic D., Stanovnik M., Kmetec A., Merlo A. Birth after treatment of a male with seminoma and azoospermia with cryopreserved-thawed testicular tissue. Hum Reprod 2000 Apr;15(4):861–4.
44. Dohle G.R., Colpi G.M., Hargreave T.B. et al. Guidelines on male infertility. Eur Urol 2005;48:703–11.
45. Perloff W.H. et al. Conception with human spermatozoa frozen by nitrogen vapor technic. Fertility and Sterility 1964;15:501–4.
46. David G. et al. The success of A.I.D. and semen characteristics: study of 1489 cycles and 192 ejaculates. International Journal of Andrology1980;3:613–9.
47. Clarke G.N. et al. Artificial insemination and in-vitro fertilization using donor spermatozoa: a report on 15 years of experience. Human Reproduction 1997;12:722–6.
48. Leibo S.P. et al. Cryopreservation of human spermatozoa. In: Vayena E. et al., eds. Current practices and controversies in assisted reproduction. Geneva, World Health Organization, 2002, p. 152–65.
49. Keel B.A., Webster B.W. Semen cryopreservation methodology and results. In: Barratt C.L.R., Cooke I.D. (eds). Donor insemination. Cambridge University Press. Cambridge, 1993, p.71–96.
50. Watson P.F. Recent developments and concepts in the cryopreservation of spermatozoa and the assessment of their postthawing function. Reproduction Fertility and Development 1995;7:871–91.
51. Bagchi A., Woods E.J., Critser J.K. Cryopreservation and vitrification: recent advances in fertility preservation technologies. Expert Rev Med Devices 2008 May;5(3):359–70.
52. Sherman J.K. Cryopreservation of human semen. In: Keel B.A., Webster B.W., eds. CRC handbook of the laboratory diagnosis and treatment of infertility. Boca Raton, CRC Press: 229–259.
53. Vutyavanich T., Piromlertamorn W., Nunta S. Rapid freezing versus slow programmable freezing of human spermatozoa. Vol. 93, issue 6, p. 1921–8.
54. Zribi N., Feki Chakroun N., El Euch H. et al. Effects of cryopreservation on human sperm deoxyribonucleic acid integrity. Fertil Steril 2010 Jan;93(1):159–66.
55. O’Flaherty C., Hales B.F. Impact of chemotherapeutics and advanced testicular cancer or Hodgkin lymphoma on sperm deoxyribonucleic acid integrity. Fertility and Sterility, vol. 94, issue 4, p. 1374–9.
56. Van der Kaaij M.A., Heutte N. et al. Sperm quality before treatment in patients with early stage Hodgkin’s lymphoma enrolled in EORTC-GELA Lymphoma Group trials. Haematologica 2009 Dec;94(12):1691–7.
57. Kulkarni S.S., Sastry P.S. et al. Gonadal function following ABVD therapy for Hodgkin’s disease. Am J Clin Oncol 1997 Aug;20(4):354–7. Hum Reprod 2004 Nov;19(11):2680.
58. Horne G., Atkinson A.D., Pease E.H. et al. Live birth with sperm cryopreserved for 21 years prior to cancer treatment: case report. Hum Reprod 2004 Jun;19(6):1448–9.
59. Woods E.J. et al. Fundamental cryobiology of reproductive cells and tissues. Cryobiology 2004;48:146–56.
60. Shin D., Lo K.C., Lipshultz L.I. Treatment options for the infertile male with cancer. J Natl Cancer Inst Monogr 2005;34:48–50.
61. Feldschuh J. et al. Successful sperm storage for 28 years. Fertility and Sterility 2005;84:1017.
62. Horne G., Atkinson A.D., Pease E.H., Logue J.P., Brison D.R., Lieberman B.A. Live birth with sperm cryopreserved for 21 years prior to cancer treatment: case report. Hum Reprod 2004 Jun;19(6):1448–9.
63. Clarke G.N. et al. Recovery of human sperm motility and ability to interact with the human zona pellucida after more than 28 years of storage in liquid nitrogen. Fertility and Sterility 2006;86:721–2.
64. Agarwal A., Ranganathan P., Kattal N., Pasqualotto F., Hallak J., Khayal S., Mascha E. Fertility after cancer: a prospective review of assisted reproductive outcome with banked semen specimens. Fertil Steril 2004 Feb;81(2):342–8.
65. Saito K., Suzuki K., Iwasaki A., Yumura Y., Kubota Y. Sperm cryopreservation before cancer chemotherapy helps in the emotional battle against cancer. Cancer 2005;104:521–4.
66. Schover L.R., Brey K., Lichtin A. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol 2002;20:1880–9.
67. Reinmuth S., Liebeskind A.K., Wickmann L., Bockelbrink A., Keil T., Henze G., Borgmann A. Having children after surviving cancer in childhood or adolescence — results of a Berlin survey. Klin Paediatr 2008 May–Jun;220(3):159–65.
68. Schover L.R., Rybicki L.A., Martin B.A. Having children after cancer: a pilot survey of survivors’ attitudes and experiences. Cancer 1999;86:697–709.
69. Волкова М.А. Клиническая онкогематология: руководство для врачей. М.: Медицина, 2007. С. 1120.
Для цитирования:
Винокуров А.А., Варфоломеева С.Р., Тарусин Д.И. Гонадотоксичность терапии лимфомы Ходжкина у подростков и молодых мужчин: актуальность проблемы и пути решения (обзор литературы). Онкогематология. 2011;6(2):12-18. https://doi.org/10.17650/1818-8346-2011-6-2-12-18
For citation:
Vinokurov A.A., Varfolomeeva S.R., Tarusin D.I. Gonadal toxicity of Hodgkin lymphoma treatment in adolescents and young males: issue relevance and ways of solve (literature review). Oncohematology. 2011;6(2):12-18. (In Russ.) https://doi.org/10.17650/1818-8346-2011-6-2-12-18
Просмотров: 501
Послать статью по эл. почте 